fda semaglutide compounding enforcement october 2025 Last month, the issued 25 warning letters to telehealth companies over what it called false or misleading claims about compounded GLP-1 medications Did the FDA Ban Compounded

Diabetes 60, 218226

Results obtained from incubating lots #A-C at 40C/75% RH (induction-sealed HDPE bottle) are shown below

These medications are intended for people with obesity or those who are overweight with related health issues

These factors create free radicalsunstable molecules that can cause oxidative stress

Patience during the first month is essentialyour body is recalibrating hunger signals and adjusting to reduced food intake

Expanding market access through regulatory gray zones can accelerate short-term revenue for telehealth platforms, but real long-term moat in bio-health still requires undeniable clinical validation I have been watching, and am not sure that the 2+ hour deliberations have moved the voting needles much